The Overall Survival Analysis of FUTURE-C-PLUS: Combination of Famitinib with Camrelizumab Plus Nab-Paclitaxel As First-Line Treatment for Advanced, Immunomodulatory Triple-Negative Breast Cancer—an Open-Label, Single-Arm, Phase 2 Trial.
Journal of Clinical Oncology（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要